Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Liabilities and Shareholders Equity (2016 - 2025)

BioCorRx's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $7.5 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 1070.58% year-over-year to $7.5 million; the TTM value through Sep 2025 reached $21.4 million, up 1070.47%, while the annual FY2024 figure was $385941.0, 0.76% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $7.5 million at BioCorRx, up from $6.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $7.5 million in Q3 2025 and bottomed at $317444.0 in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $819249.0 (2022), against an average of $1.9 million.
  • The largest annual shift saw Liabilities and Shareholders Equity tumbled 59.24% in 2022 before it soared 2042.45% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $819975.0 in 2021, then fell by 6.51% to $766594.0 in 2022, then tumbled by 49.27% to $388887.0 in 2023, then dropped by 0.76% to $385941.0 in 2024, then skyrocketed by 1851.98% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Liabilities and Shareholders Equity are $7.5 million (Q3 2025), $6.7 million (Q2 2025), and $6.8 million (Q1 2025).